C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation

Maggie E Jones-Carr; Huma Fatima; Vineeta Kumar; Douglas J Anderson; Julie Houp; Jackson C Perry; Gavin A Baker; Leigh McManus; Andrew J Shunk; Paige M Porrett; Jayme E Locke

doi:10.1172/JCI175996

C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation

J Clin Invest. 2024 Jan 25;134(5):e175996. doi: 10.1172/JCI175996.

Affiliations

¹ Department of Surgery, Division of Transplantation.
² Department of Pathology, and.
³ Department of Medicine, Division of Nephrology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁴ Legacy of Hope, Birmingham, Alabama, USA.

No abstract available

Keywords: Complement; Innate immunity; Nephrology; Organ transplantation; Transplantation.

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Kidney*
Swine
Thrombotic Microangiopathies* / drug therapy
Thrombotic Microangiopathies* / prevention & control
Transplantation, Heterologous

Substances

eculizumab
Antibodies, Monoclonal, Humanized

Grants and funding

United Therapeutics and its subsidiaries Lung Biotechnology PBC and Revivicor provided grant support for this research. The funder did not play a role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation or review of the manuscript; or in the decision to submit the manuscript for publication.